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The conversion of soluble peptides and proteins into amyloid ﬁbrils and/or intermediate oligomers
is believed to be the central event in the pathogenesis of most human neurodegenerative diseases.
Existing treatments are at best symptomatic. Accordingly, small molecule inhibitors of amyloid
ﬁbril formation and their mechanisms are of great interest. Here we report that the conformational
changes undergone by a -synuclein as it assembles into amyloid ﬁbrils can be detected by epitope-
speciﬁc antibodies. We show that the conformations of polyphenol-bound a-synuclein monomers
and dimers differ from those of unboundmonomers and resemble amyloid ﬁbrils. This strongly sug-
gests that small molecule inhibitors bind and stabilize intermediates of amyloid ﬁbril formation,
consistent with the view that inhibitor-bound molecular species are on-pathway intermediates.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The conversion of a small number of soluble peptides and pro-
teins into amyloid ﬁbrils and/or intermediate oligomers is believed
to be the central event in the pathogenesis of most neurodegener-
ative diseases. Three proteins, b-amyloid, tau and a-synuclein,
make up the abnormal deposits in the vast majority of disease
cases [1,2]. Many current therapeutic strategies are aimed at inhib-
iting ﬁlament formation and at promoting ﬁlament clearance. In
recent years, a number of compounds has been identiﬁed that pre-
vent amyloid ﬁbril formation in vitro [3–10]. In the absence of
effective therapies for neurodegenerative diseases, it is important
to understand the mechanisms of action of these compounds.
We previously reported that non-toxic, SDS-stable dimers and
oligomers of tau and a-synuclein formed in the presence of inhib-
itory compounds and that their formation closely correlated with
the inhibition of ﬁbril formation [8,9]. This suggests that smallchemical Societies. Published by E
wa), mg@mrc-lmb.cam.ac.ukmolecule inhibitors stabilize non-toxic, on-pathway intermediates.
Based on these observations, we presented a model for the inhibi-
tion of tau, a-synuclein and Ab aggregation by small molecules.
Ehrnhoefer et al. recently presented a different model for the inhi-
bition of ﬁbril formation of a-synuclein and Ab by the small mole-
cule inhibitor ()-epigallocatechin-3-gallate (EGCG) [11]. They
reported that EGCG inhibited the assembly of a-synuclein and Ab
by binding to natively unfolded protein monomers, preventing
their conversion into toxic on-pathway aggregation intermediates.
Instead, a-synuclein and Ab formed unstructured, non-toxic oligo-
mers that were said to be off-pathway.
In this study, we used 10 epitope-speciﬁc antibodies of a-syn-
uclein spanning the whole of a-synuclein and investigated their
reactivities with monomeric a-synuclein and with a-synuclein ﬁ-
brils. Some antibodies detected conformational changes that dis-
tinguished monomers from ﬁbrils. These antibodies were then
used to detect conformational changes in polyphenol-stabilized
monomers and dimers of a-synuclein. Importantly, SDS-stable,
polyphenol-stabilized monomers and dimers showed an interme-
diate reactivity between that of monomers and ﬁbrils. These
ﬁndings indicate that inhibitory compounds bind and stabilize
on-pathway intermediates of amyloid ﬁbril formation.lsevier B.V. All rights reserved.
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2.1. Antibodies
Polyclonal antibodies were raised against synthetic peptides
corresponding to residues 1–10, 11–20, 21–30, 31–40, 41–50,
51–60, 61–70, 75–91 and 131–140 of human a-synuclein, with
Cys at the C-terminus or the N-terminus (Greiner Bio-One Co.
Ltd.) (Table 1). The peptides were conjugated to m-male-
imidobenzoyl-N-hydrosuccinimide ester-activated keyhole limpet
hemocyanin (KLH). The KLH-peptide complex (1 mg of each immu-
nogen) emulsiﬁed in Freund’s complete adjuvant was injected sub-
cutaneously into a New Zealand White rabbit, followed by 5
weekly subcutaneous injections of 150 lg KLH-peptide complex
emulsiﬁed in Freund’s incomplete adjuvant, starting 3 weeks after
the ﬁrst immunization. Antibody Syn259, which recognizes resi-
dues 104–119 of a-synuclein, was kindly provided by Dr. S. Nakajo.
2.2. Expression and puriﬁcation of a-synuclein
Human a-synuclein was expressed in E. coli BL21 (DE3) cells, as
described [9]. To avoid the production of a-synuclein dimers in-
duced by misexpression of cysteine-containing a-synuclein, the
Y136-TAT construct was used [12]. a-Synuclein was puriﬁed by
boiling, Q-Sepharose ion exchange chromatography and ammo-
nium sulfate precipitation, followed by dialysis against 30 mM
Tris–HCl, pH 7.5, and the determination of protein concentrations,
as described [9].
2.3. Preparation of a-synuclein ﬁbrils and inhibitor-bound monomers
and dimers
Puriﬁed a-synuclein (7 mg/ml) was incubated at 37 C in a
shaking incubator (200 rpm) in 30 mM Tris–HCl, pH 7.5, containing
0.1% NaN3, for 72 h. Fibrils were pelleted by spinning the assembly
mixtures at 113000g for 20 min. To prepare SDS-stable, inhibi-
tor-boundmonomers and dimers, the polyphenol exifone was used
in most experiments [9]. Similar results were obtained with dopa-
mine and gossypetin, two previously described inhibitory
compounds [4,9]. Exifone-bound a-synuclein monomers (Exi-
monomer) and dimers (Exi-dimer) were prepared by gel ﬁltration,
as described [9]. Brieﬂy, a-synuclein (7 mg/ml) was incubated in
the presence of 2 mM inhibitory compound at 37 C for 72 h in
30 mM Tris-HCl containing 0.1% sodium azide, and centrifuged at
113000g for 20 min. The supernatants were loaded onto a
Superdex 200 gel ﬁltration column (1  30 cm), eluted in 10 mM
Tris–HCl, pH 7.5, containing 150 mM NaCl, and monitored at
214 nm. Fractionated samples were analyzed by SDS–PAGE and
immunoblotting. Protein concentrations were determined as de-
scribed [9].Table 1
Antigen peptides for immunization of rabbits.
Name of antibodies AA residues Antigen peptide
Syn1-10 1–10 MDVFMKGLSKC
Syn11-20 11–20 AKEGVVAAAEC
Syn21-30 21–30 KTKQGVAEAAC
Syn31-40 31–40 GKTKEGVLYVC
Syn41-50 41–50 GSKTKEGVVHC
Syn51-60 51–60 GVATVAEKTKC
Syn61-70 61–70 EQVTNVGGAVC
Syn75-91 75–91 CTAVAQKTVEGAGSIAAA
Syn131-140 131–140 CEGYQDYEPEA2.4. ELISA and dot blot assay
For the ELISA, peptide immunogens, a-synuclein monomers and
ﬁbrils, as well as Exi-monomers and dimers (0.5–1.0 lg/well in
50 mM Tris–HCl, pH 8.8) were coated onto microtitre plates
(SUMILON) at 4 C for 16 h. The plates were blocked with 10% fetal
bovine serum (FBS) in PBS, incubated with the ﬁrst antibody di-
luted in 10% FBS/PBS at room temperature for 1.5 h, followed by
incubation with HRP-goat anti-rabbit IgG (Bio-Rad) at 1:1000 dilu-
tion, and reacted with the substrate, 0.4 mg/ml o-phenylendi-
amine, in citrate buffer (24 mM citric acid, 51 mM Na2HPO4), The
absorbance at 490 nm was measured using Plate Chameleon
(HIDEX). For the dot blot assay, 100 ng a-synuclein was spotted
onto a PVDF membrane by using a dot blot apparatus (Bio-Rad).
Membranes were stained with Coomassie Brilliant Blue or blocked
with 3% gelatin/PBS and incubated overnight at room temperature
with anti-a-synuclein antibodies in 10% FBS/PBS. Immunoreactiv-
ity was detected with avidin-biotin (Vector Laboratories) and
developed using NiCl-enhanced diaminobenzidine. The rate of
reactivity was quantiﬁed by scanning densitometry and expressed
relative to the density of a-synuclein ﬁbrils (taken as 100%).3. Results
3.1. Antibody speciﬁcities
In order to detect conformational changes in a-synuclein, anti-
bodies were raised against nine peptides (corresponding to resi-
dues 1–10, 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, 75–91
and 131–140) (Table 1). The speciﬁcities of the antibodies were
analyzed by ELISA. The peptides used as immunogens were coated
on a plate and probed with each antibody. As shown in Fig. 1, each
antibody reacted strongly with the appropriate peptide, but hardly
with the other peptides. Antibody Syn41–50 was an exception, in
that it weakly recognized peptides 11–20 and 31–40, in addition
to recognizing peptide 41–50 very strongly.
3.2. Analysis of conformational changes in a-synuclein using epitope-
speciﬁc antibodies
We investigated the reactivity of monomeric a-synuclein and of
a-synuclein ﬁbrils by dot blot assay using the nine antibodies de-
scribed above and antibody Syn259 whose epitope corresponds to
residues 104–119 of a-synuclein. Monomeric a-synuclein was
strongly detected by antibodies to the C-terminal region (Syn259
and Syn131–140), but not by antibodies to the N-terminal or mid-
dle region (Fig. 2). This is in good agreement with previous reports
showing that the C-terminal region of a-synuclein is unfolded and
shields the N-terminal and central regions by way of long-range
intramolecular interactions [13,14]. In contrast, a-synuclein ﬁbrils
were strongly immunoreactive with all antibodies (Fig. 2), indicat-
ing that the relevant epitopes were accessible. This is also
consistent with current knowledge of the location of individual
b-strands and their connecting loops in the structure of the a -syn-
uclein ﬁbril [15,16]. These results indicate that conformational
changes undergone by a-synuclein as it assembles into ﬁbrils can
be detected immunochemically. We next analyzed the conforma-
tions of exifone-stabilized monomers and dimers of a-synuclein,
following their separation by gel ﬁltration chromatography (Sup-
plementary Fig.). SDS-stable dimers formed in the presence of exif-
one were recognized by antibodies speciﬁc for Syn1–10, Syn11–20,
Syn21–30, Syn31–40 and Syn41–50 (Fig. 2). They were less well
recognized by antibodies speciﬁc for Syn51–60, Syn61–70 and
Syn75–91. The antibody recognition patterns of SDS-stable mono-
mers formed in the presence of exifone were intermediate between
Fig. 1. Speciﬁcities of anti-peptide antibodies spanning the whole of a-synuclein
determined by ELISA. Synthetic peptides (0.5 lg/well) were coated on a 96-well
microtitre plate for 16 h at 4 C and each of the 9 peptides was probed with each of
the 9 antisera.
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(Fig. 2). All antibodies gave similar results by ELISA (data not
shown).
4. Discussion
We show here that the conformational changes undergone by
a-synuclein during the conversion from monomers to amyloid ﬁ-Fig. 2. Dot blot analysis of monomeric a-synuclein, the a-synuclein ﬁbril, as well as exif
10 antibodies whose epitopes span the whole of human a-synuclein. The relative intens
immunoreactivity (taken as 100, n = 3). Each dot corresponds o 100 ng of a-synuclein.brils can be detected by epitope-speciﬁc antibodies. Antibodies to
the C-terminal region of a-synuclein recognized monomers and ﬁ-
brils almost equally, whereas antibodies to the N-terminal region
strongly reacted with ﬁbrils, but labelled monomers only weakly.
Under physiological conditions, a-synuclein is known to populate
an ensemble of conformations, including conformers that are more
compact than expected for a random coil protein [17–19]. Our
ﬁndings indicating that the N-terminal region is buried and only
poorly accessible to antibodies, are in line with this work. They
are also in agreement with reports showing that the C-terminal re-
gion of a-synuclein is unfolded and shields the N-terminal and
central regions by way of long-range intramolecular interactions
[13,14].
The core of the ﬁbril spans approximately residues 30–100 of a-
synuclein [20,21] and is believed to comprise ﬁve parallel b-
strands that are separated by ﬂexible loops [16]. Our ﬁndings on
a-synuclein ﬁbrils are consistent with the loop regions being anti-
body-accessible. Conformational changes detectable by speciﬁc
antibodies have previously been reported in tau, another natively
unfolded protein, as it assembles into abnormal ﬁlaments. Thus,
antibody Alz50 reacts more strongly with paired helical ﬁlament
tau from Alzheimer’s disease brain than with the soluble mono-
meric protein [22].
Inhibitor-bound dimers and monomers of a-synuclein were
tested using the same panel of antibodies. When bound to the pol-
yphenol exifone, dimers of a-synuclein were detected by antibod-
ies to the N-terminal region in a manner similar to ﬁbrils. Unlike
the latter, inhibitor-bound dimers were not recognized by antibod-
ies to the middle region of a-synuclein. Antibodies to the C-termi-
nal region recognized inhibitor-bound dimers and ﬁbrils equally.
Relative to unbound monomers, therefore, inhibitor-bound a-syn-
uclein dimers are characterized by a more accessible N-terminal
region. NMR spectroscopy of exifone-stabilized a-synuclein dimers
and nitroblue tetrazolium staining of cleaved exifone-bound a-one-stabilized a-synuclein monomers (Exi-monomer) and dimers (Exi-dimer), with
ities of immunoreactivity are indicated below the dots and expressed as % of ﬁbril
Fig. 3. Model of the inhibition of a-synuclein ﬁbril formation by small molecules.
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formation and that exifone binds to these regions (in preparation).
Dimers of a-synuclein are believed to play a key role in the aggre-
gation process [23]. A recent study has also shown that aggrega-
tion-inhibiting molecules interact with N-terminal regions of
a-synuclein [24]. When tested with the panel of antibodies, inhib-
itor-bound monomers of a-synuclein gave a pattern intermediate
between that of unbound monomers and inhibitor-bound dimers.
Taken together, our ﬁndings suggest the existence of a linear path-
way leading from monomeric to ﬁbrillar a-synuclein, with exifone
binding to misfolded monomers and dimers, thereby preventing ﬁ-
bril formation. A similar mechanism may underlie the inhibition of
a-synuclein ﬁbril formation by the molecular chaperone Hsp70
[25].
This interpretation is at odds with a recent study reporting that
oligomers of a-synuclein and Ab formed in the presence of EGCG
were off-pathway [11]. In this study, conformation-speciﬁc anti-
body A11, which recognizes an oligomeric state that is believed
to be common to many amyloidogenic proteins [26], did not detect
EGCG-induced oligomers. This antibody is believed to be speciﬁc
for on-pathway toxic oligomers of a-synuclein. However, Ehrnhoe-
fer et al. found that it recognized His-tagged monomeric a-synuc-
lein [11]. In our hands, antibody A11 also recognized a-synuclein
ﬁbrils (unpublished observation).
Single molecule studies have shown that a-synuclein exists as
three distinct conformers in vitro that are characterized by: long-
distance weak interactions, random coil and b-like structures
[27]. The b-like conformer has been linked to the process of a-syn-
uclein aggregation. It is tempting to suggest that exifone binds to
this conformer, in line with the ﬁnding that inhibitory compounds
inhibit amyloid ﬁbril formation at substoichiometric concentra-
tions [8,9]. Our previous work on the ordered aggregation of tau
protein has also shown that small molecule inhibitors bind to olig-
omers and ﬁlaments, but not to native monomers [8]. A revised
model for the inhibition of a-synuclein ﬁbril formation by small
molecules is shown in Fig. 3. Monomeric a-synuclein exists in a na-
tive conformation, with a small proportion of b-like structure. Dur-
ing assembly, the latter may dimerize, oligomerize and form
amyloid seeds. Amyloid ﬁbrils can grow from these seeds. Smallmolecule inhibitors bind to misfolded monomers, dimers and olig-
omers, thus preventing ﬁbril formation.Acknowledgements
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